Gossamer Bio Inc. (GOSS) carries a Roarable Rating of E (Strong Sell) with 33/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-02, Gossamer Bio Inc. (NASDAQ: GOSS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $10.38 (-2.90% 1D, market cap $65.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GOSS ranks #750 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GOSS carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CPIX (Cumberland Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -16.4%, cap $65.2M) and SPRO (Spero Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E 7.5x, ROIC 26.6%, cap $64.6M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
Per GOSS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001728117), Gossamer Bio Inc. generated $48.5M in revenue (-57.7% YoY), -$170.4M in net income, and -$171.3M in free cash flow against $172.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While GOSS currently carries a cautious 33/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($11.26) and Max Pain ($10.90) forces dealer call-delta covering toward $325.08.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Gossamer Bio Inc. (GOSS) dropped -2.90% to $10.38, trading at 2% of its 52-week range ($8.29 – $309.6). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Gossamer Bio’s updated model now points to a fair value of $95.40, up from $82.48, which marks a meaningful shift in the price target assumptions for the stock. Recent Street research links these higher targets to differ
Chardan Capital analyst Andreas Argyrides initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Buy rating and announces Price Target of $160.
Adobe downgraded, VF Corp. upgraded: Wall Street's top analyst calls
Gossamer Bio’s modeled fair value has shifted from US$1.66 to US$82.48, reflecting the 1 for 80 reverse stock split and refreshed valuation work. Street research links these reset price targets to a split view on risk an
SAN DIEGO, September 23, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment
SAN DIEGO, September 11, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment
Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The pulmonary arterial hype
SAN DIEGO, September 04, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hyperte
Gossamer Bio, Inc. (NASDAQ:GOSS) announced a structured private placement on August 21 that could generate up to approximately $250 million in gross proceeds. However, Gossamer Bio, Inc. (NASDAQ:GOSS) divided the financi
The proceeds will help advance seralutinib's clinical development and potential commercialisation.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -57.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on GOSS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for GOSS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Gossamer Bio Inc. (GOSS) ranks #750 by composite RQD confidence (33/100, grade E) and #717 by equity capitalization ($65.4M). Within this direct 5-issuer industry benchmark cohort, SPRO leads on earnings valuation at 7.5x trailing P/E, while SPRO leads on capital efficiency and profitability with 26.6% ROIC and — gross margin. SPRO currently holds the highest overall quantitative score in the immediate peer group at 43/100 (D-) compared with GOSS at 33/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| GOSS
ACTIVE
Gossamer Bio Inc. | E | 33/100 | — | — | -35.0% | -2.90% | $65.4M | Benchmark Subject |
| CPIX Cumberland Pharmaceuticals Inc. | D- | 38/100 | — | 85.0% | -16.4% | +7.82% | $65.2M | /cpix-vs-goss → |
| SPRO Spero Therapeutics Inc. | D- | 43/100 | 7.5x | — | 26.6% | -4.50% | $64.6M | /spro-vs-goss → |
| FBIO Fortress Biotech Inc. | D- | 39/100 | — | 66.9% | -35.0% | -4.00% | $66.7M | /fbio-vs-goss → |
| RNXT RenovoRx Inc. | E | 31/100 | — | 70.9% | -35.0% | -10.74% | $67.2M | /rnxt-vs-goss → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Gossamer Bio Inc. (GOSS) reported GAAP revenue of $48.5M (-57.7% vs. FY2024 revenue of $114.7M ) , GAAP net income of -$170.4M, operating cash flow of -$171.3M, and free cash flow of -$171.3M (-4840.7% YoY). On the balance sheet, GOSS closed FY2025 with $172.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $48.5M | -$170.4M | -$171.3M | -$171.3M | $172.2M | — |
| FY2024 (FY) | 2024-12-31 | $114.7M | -$56.5M | -$3.5M | -$3.5M | $315.3M | $0 |
| FY2023 (FY) | 2023-12-31 | $0 | -$179.8M | -$159.2M | -$159.2M | — | — |
As of 2026-11-02, Gossamer Bio Inc. (NASDAQ: GOSS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 33/100 at a spot price of $10.38 (-2.90% 1D, market cap $65.4M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, GOSS ranks #750 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GOSS carries a Roarable E (33/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CPIX (Cumberland Pharmaceuticals Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -16.4%, cap $65.2M) and SPRO (Spero Therapeutics Inc.) posts a D- grade (43/100 RQD, P/E 7.5x, ROIC 26.6%, cap $64.6M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
Per GOSS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001728117), Gossamer Bio Inc. generated $48.5M in revenue (-57.7% YoY), -$170.4M in net income, and -$171.3M in free cash flow against $172.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
GOSS last traded at $10.38 (-2.90% on volume of 179,576 shares), positioning the stock -7.82% below its 50-day simple moving average ($11.26) and -74.79% below its 200-day simple moving average ($41.18). Across its 52-week range of $8.29 to $309.60, GOSS sits at the 0.7% percentile with a 14-day RSI of 51.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($9.08 to $11.68).
Why GOSS Stock dropped -2.90% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Per the Roarable RQD 5-pillar rating engine, Gossamer Bio Inc. (GOSS) carries a composite score of 33 / 100 (E — Roarable Strong Sell — Forensic Risk / Avoid).\n- Fundamental Cash Engine (6 / 20): Return on invested capital (ROIC) registers at -35.0% with a free cash flow yield of 0.00% and gross margin of 0.0%.\n- Institutional 13F Whale Flow (8 / 20): Tracks institutional accumulation and dark-pool/options positioning relative to the Biotechnology: Pharmaceutical Preparations cohort.\n- Insider & Congressional Conviction (3 / 20): Evaluates open-market Form 4 executive purchases and Congressional PTR disclosures.\n- Macro Regime Fit (8 / 20): Equity beta of 1.00 across the Health Care sector.\n- Forensic Balance-Sheet Shield (8 / 20): Altman Z-Score of 2.50, Piotroski F-Score of 1/9, and Debt-to-Equity of 0.50.
Gossamer Bio Inc. (GOSS) is a NASDAQ-listed Health Care issuer operating in Biotechnology: Pharmaceutical Preparations with a market capitalization of $0.1B.
Operating within Biotechnology: Pharmaceutical Preparations (Health Care), GOSS exhibits an operating margin of -60.0% and net margin of -60.0%. Prospective investors should monitor 2nd-order capex cycles, input cost pass-through in gross margin (0.0%), and valuation discipline (current multiple) relative to free cash flow conversion.
Real-time company headlines, analyst actions, and sector developments for Gossamer Bio Inc. (GOSS) • Click "Debate This Headline" to argue it in the Roar Pit below
Gossamer Bio’s updated model now points to a fair value of $95.40, up from $82.48, which marks a meaningful shift in the price target assumptions for the stock. Recent Street research links these higher targets to differ
Chardan Capital analyst Andreas Argyrides initiates coverage on Gossamer Bio (NASDAQ:GOSS) with a Buy rating and announces Price Target of $160.
Adobe downgraded, VF Corp. upgraded: Wall Street's top analyst calls
Gossamer Bio’s modeled fair value has shifted from US$1.66 to US$82.48, reflecting the 1 for 80 reverse stock split and refreshed valuation work. Street research links these reset price targets to a split view on risk an
SAN DIEGO, September 23, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment
SAN DIEGO, September 11, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS) (the "Company" or "Gossamer"), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment
Dublin, Sept. 08, 2026 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension - Market Insight, Epidemiology, and Market Forecast - 2036" has been added to ResearchAndMarkets.com's offering. The pulmonary arterial hype
SAN DIEGO, September 04, 2026--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hyperte
Welcome to the GOSS (Gossamer Bio Inc.) Roar Pit. Current RQD Composite is 33/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
Everyone in here is repeating the bull case on GOSS, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Gossamer Bio Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
Looking at the 5-pillar RQD breakdown on GOSS, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $10.38 (52-wk range $8.29 - $309.60), any beat on forward guidance forces shorts and underweight funds to chase.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).